Biomerica (BMRA) Price-to-Projected Revenue Ratio

Biomerica Inc (BMRA) - corporate logo

Biomerica, Inc. (BMRA) leverages its patented food intolerance analysis methods to maintain significant pricing power. The projected market cap-to-revenue ratio confirms this status, with the parameter reaching 1.40. The company is scaling the implementation of InFoods systems to combat IBS, thereby expanding its market influence, although gastroenterologist loyalty is constrained by strict FDA oversight of at-home diagnostics.

BMRA biomerica.com: Forward Price-to-Revenue Multiple in the range 07/04/2022 - 11/16/2026

Comprehensive metric breakdowns and analytics for Biomerica, Inc. (BMRA)

- current price and projected stock value:
Comprehensive company analysis:Biomerica Inc BMRA
Original product of Biomerica Inc

Biomerica, Inc. (BMRA) strategic alliances in rapid diagnostics and personalized nutrition directly determine the scale of future cash flows. The company's future P/S dynamics reflect the ratio of market value to expected revenue, serving as an indicator of a fundamental pivot and the speed of commercial recovery, which allows investors to assess the business's margin of safety and the risk of inflated expectations ahead of a potential correction.

Competitors of Biomerica, Inc. (BMRA)

Forward P/S Multiple A (agilent.com)|Quest Corp (DGX) - Market Cap to Future Revenue Ratio|ILMN - Price-to-Projected Revenue Ratio|EXAS - Forward P/S Multiple|RVTY (Revvity) - Forward Price-to-Revenue Multiple|Bio-Rad - Forward Price to Sales|Price-to-Projected Revenue Ratio anbio.com|Forward P/S Multiple Sotera Health Company|Price-to-Projected Revenue Ratio QuidelOrtho (QDEL)|OPK - Market Cap to Future Revenue Ratio|caredx.com - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Maravai LifeSciences Corp (MRVI)|FLGT: Forward Price-to-Revenue Multiple|Forward Price to Sales LAB (Fluidigm)|Cytek Biosciences Inc (CTKB) - Price-to-Projected Revenue Ratio|OSUR: Price to Expected Revenue Ratio|Forward Price-to-Revenue Multiple XGN|MDXH: Forward Price to Sales|Price-to-Projected Revenue Ratio Lucid Diagnostics Inc. (LUCD)|Price-to-Projected Revenue Ratio PRE (Prenetics Global Limited)|Forward P/S Multiple IMDX (Insight Molecular Diagnostics Inc)|Price to Expected Revenue Ratio TRIB (Trinity Biotech Corp)|PRPH - Price-to-Projected Revenue Ratio|Ainos (AIMD) - Forward Price-to-Revenue Multiple|CoDx (CODX) - Price-to-Projected Revenue Ratio|HSCS (Heart Test Labs) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple CDIO|Market Cap to Future Revenue Ratio onconetix.gcs-web.com ONCO|Price-to-Projected Revenue Ratio Virax Biolabs (VRAX)|Price to Expected Revenue Ratio BJDX|Price-to-Projected Revenue Ratio Vermillion AWH|Accelerate Diagnostics Inc (AXDX) - Market Cap to Future Revenue Ratio|centogene.com - Forward P/S Multiple|ENZ (Enzo Biochem Inc.) - Market Cap to Projected Revenue|Market Cap to Future Revenue Ratio FRES|Market Cap to Future Revenue Ratio GTG Labs (GENE)|ME (23andme.com) - Forward P/S Multiple|Forward P/S Multiple Psychemedics Inc